The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
The efficacy of sodium-glucose transporter 2 (SGLT-2) inhibitors for nonalcoholic fatty liver disease (NAFLD) is unclear. Therefore, we conducted a systematic review and meta-analysis to evaluate SGLT-2 inhibitors efficacy for NAFLD treatment. We systematically searched major electronic databases (P...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Pharmacological Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661825000726 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823859431723499520 |
|---|---|
| author | Hongsheng Li Yanli Hou Wenyong Xin Lina Ding Ying Yang Yikun Zhang Wenqi Wu Zhibin Wang Wenyu Ding |
| author_facet | Hongsheng Li Yanli Hou Wenyong Xin Lina Ding Ying Yang Yikun Zhang Wenqi Wu Zhibin Wang Wenyu Ding |
| author_sort | Hongsheng Li |
| collection | DOAJ |
| description | The efficacy of sodium-glucose transporter 2 (SGLT-2) inhibitors for nonalcoholic fatty liver disease (NAFLD) is unclear. Therefore, we conducted a systematic review and meta-analysis to evaluate SGLT-2 inhibitors efficacy for NAFLD treatment. We systematically searched major electronic databases (PubMed, Cochrane Library, Web of Science, Embase) from inception until 11/2023, identifying randomized controlled trials (RCTs) of SGLT-2 inhibitors treatment for patients with NAFLD. The mean differences (MD or SMD) and 95 % confidence intervals (CIs) were calculated via random-effects models. Eleven articles (n = 805 patients with NAFLD) were included in this study. Of these, 408 participants received SGLT-2 inhibitors, while 397 participants were in the control group. SGLT-2 inhibitors significantly reduced liver enzyme levels, including aspartate alanine aminotransferase (ALT) (MD [95 % CI]; −9.31 U/L [-13.41, −5.21], p < 0.00001), aspartate aminotransferase (AST) (MD [95 % CI]; −6.06 U/L [-10.98, −1.15], p = 0.02), and gamma-glutamyltransferase (GGT) (MD [95 % CI]; −11.72 U/L [-15.65, −7.80], p < 0.00001). SGLT-2 inhibitors intervention was also associated with significant reductions in body weight (MD [95 % CI]; −2.72 kg [-3.49, −1.95], p < 0.00001) and BMI (MD [95 % CI]; −1.11 kg/m2 [-1.39, −0.82], p < 0.00001) and improvements in glycaemic indices, triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C). However, no significant changes in total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C) were observed. The meta-analysis revealed a beneficial effect of SGLT-2 inhibitors on liver functions and body weight, BMI, TG, HDL-C, and glucose homeostasis in patients with NAFLD, indicating that SGLT-2 inhibitors might be a clinical therapeutic strategy for these patients, especially individuals with concurrent type 2 diabetes mellitus (T2DM). |
| format | Article |
| id | doaj-art-de493b7a9d7649529f2f581d37558d44 |
| institution | Kabale University |
| issn | 1096-1186 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pharmacological Research |
| spelling | doaj-art-de493b7a9d7649529f2f581d37558d442025-02-11T04:33:34ZengElsevierPharmacological Research1096-11862025-03-01213107647The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysisHongsheng Li0Yanli Hou1Wenyong Xin2Lina Ding3Ying Yang4Yikun Zhang5Wenqi Wu6Zhibin Wang7Wenyu Ding8Endocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, China; Jinan Key Laboratory of Translational Medicine on Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, ChinaEndocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, China; Jinan Key Laboratory of Translational Medicine on Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, China; Shandong Institute of Endocrine and Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, ChinaDepartment of Retirement Affairs, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, ChinaEndocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, China; Jinan Key Laboratory of Translational Medicine on Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, China; Shandong Institute of Endocrine and Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, ChinaEndocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, China; Shandong Institute of Endocrine and Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, ChinaEndocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, China; Shandong Institute of Endocrine and Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, ChinaEndocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, China; Jinan Key Laboratory of Translational Medicine on Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, ChinaEndocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, China; Jinan Key Laboratory of Translational Medicine on Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, China; Shandong Institute of Endocrine and Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, China; Corresponding authors at: Endocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, China.Endocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, China; Jinan Key Laboratory of Translational Medicine on Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, China; Shandong Institute of Endocrine and Metabolic Diseases, 18877, Jingshi Rd, Jinan 250062, China; Corresponding authors at: Endocrine and Metabolic Diseases Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, 18877, Jingshi Rd, Jinan 250062, China.The efficacy of sodium-glucose transporter 2 (SGLT-2) inhibitors for nonalcoholic fatty liver disease (NAFLD) is unclear. Therefore, we conducted a systematic review and meta-analysis to evaluate SGLT-2 inhibitors efficacy for NAFLD treatment. We systematically searched major electronic databases (PubMed, Cochrane Library, Web of Science, Embase) from inception until 11/2023, identifying randomized controlled trials (RCTs) of SGLT-2 inhibitors treatment for patients with NAFLD. The mean differences (MD or SMD) and 95 % confidence intervals (CIs) were calculated via random-effects models. Eleven articles (n = 805 patients with NAFLD) were included in this study. Of these, 408 participants received SGLT-2 inhibitors, while 397 participants were in the control group. SGLT-2 inhibitors significantly reduced liver enzyme levels, including aspartate alanine aminotransferase (ALT) (MD [95 % CI]; −9.31 U/L [-13.41, −5.21], p < 0.00001), aspartate aminotransferase (AST) (MD [95 % CI]; −6.06 U/L [-10.98, −1.15], p = 0.02), and gamma-glutamyltransferase (GGT) (MD [95 % CI]; −11.72 U/L [-15.65, −7.80], p < 0.00001). SGLT-2 inhibitors intervention was also associated with significant reductions in body weight (MD [95 % CI]; −2.72 kg [-3.49, −1.95], p < 0.00001) and BMI (MD [95 % CI]; −1.11 kg/m2 [-1.39, −0.82], p < 0.00001) and improvements in glycaemic indices, triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C). However, no significant changes in total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C) were observed. The meta-analysis revealed a beneficial effect of SGLT-2 inhibitors on liver functions and body weight, BMI, TG, HDL-C, and glucose homeostasis in patients with NAFLD, indicating that SGLT-2 inhibitors might be a clinical therapeutic strategy for these patients, especially individuals with concurrent type 2 diabetes mellitus (T2DM).http://www.sciencedirect.com/science/article/pii/S1043661825000726Sodium-glucose transporter 2 inhibitorsNonalcoholic fatty liver diseaseLiver enzymesMeta-analysis |
| spellingShingle | Hongsheng Li Yanli Hou Wenyong Xin Lina Ding Ying Yang Yikun Zhang Wenqi Wu Zhibin Wang Wenyu Ding The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis Pharmacological Research Sodium-glucose transporter 2 inhibitors Nonalcoholic fatty liver disease Liver enzymes Meta-analysis |
| title | The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis |
| title_full | The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis |
| title_fullStr | The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis |
| title_full_unstemmed | The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis |
| title_short | The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis |
| title_sort | efficacy of sodium glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease a systematic review and meta analysis |
| topic | Sodium-glucose transporter 2 inhibitors Nonalcoholic fatty liver disease Liver enzymes Meta-analysis |
| url | http://www.sciencedirect.com/science/article/pii/S1043661825000726 |
| work_keys_str_mv | AT hongshengli theefficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT yanlihou theefficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT wenyongxin theefficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT linading theefficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT yingyang theefficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT yikunzhang theefficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT wenqiwu theefficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT zhibinwang theefficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT wenyuding theefficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT hongshengli efficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT yanlihou efficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT wenyongxin efficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT linading efficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT yingyang efficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT yikunzhang efficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT wenqiwu efficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT zhibinwang efficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis AT wenyuding efficacyofsodiumglucosetransporter2inhibitorsinpatientswithnonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis |